department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Ozurdex · pharmadog

pharmadog
drugs
Ozurdex

drug

patient view →

dexamethasone LA

Marketedupdated 2mo ago

by $ABBV AbbVie Inc.

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 75 approved and 174 investigational indications.

indications

investigational

Diabetic Macular Edema

all catalysts(14)

approval · 14

view all 14 catalysts →

News(0)

no news has mentioned this drug yet

brand

Ozurdex

generic

dexamethasone

MOA

12.1 Mechanism of Action Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.

indication

Branch Retinal Vein Occlusion

phase

marketed

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

OZURDEX (DEXAMETHASONE) — FDA approval

dexamethasone LA

Data sources

openFDA · ClinicalTrials.gov

last refreshed just now

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 7, 2028

~1.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

Apr 26, 2041method-of-use (U-1680)US 12144889
Jun 23, 2039formulationUS 11097061
Nov 16, 2037method-of-use (U-3455)US 11458041
Oct 7, 2036method-of-use (U-3455)US 12150896
Jun 22, 2034method-of-use (U-2340)US 10022502
May 23, 2034method-of-use (U-2340)US 10028965
May 23, 2034formulationUS 10159683
May 11, 2032formulationUS 10799642
May 14, 2030formulationUS 84096063.9y
Feb 12, 2030method-of-use (U-2487)US 85630273.6y

FDA exclusivities (1)

Apr 7, 2028NPPNew Product (3y)1.8y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

🐶 often sniffed alongside

top 3

drugdexamethasone SR28 co-mentions · 14 sources
tagApproval28 co-mentions · 14 sources
drugOZURDEX14 co-mentions · 14 sources

Trials studying dexamethasone LA

phase2A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myelomaactive not recruitingn=208
phase3A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphomaactive not recruitingn=501
phase1Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myelomacompletedn=3
phase3Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Boneterminatedn=11
phase1RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancerterminatedn=15
phase2Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosisrecruitingn=53
phase3A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)active not recruitingn=281
phase3MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)recruitingn=492

more trials →